Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice

被引:0
|
作者
Nanni, P
Nicoletti, G
De Giovanni, C
Croci, S
Astolfi, A
Landuzzi, L
Di Carlo, E
Iezzi, M
Musiani, P
Lollini, PL
机构
[1] Univ Bologna, Canc Res Sect, Dept Expt Pathol, I-40126 Bologna, Italy
[2] Ist Ortoped Rizzoli, I-40136 Bologna, Italy
[3] Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rhabdomyosarcomas derive from the skeletal muscle lineage and harbor a variety of genetic and molecular lesions. However, it is not clear which molecular alterations have a pathogenetic role. We show that activation of the HER-2/neu oncogene coupled with inactivation of the oncosuppressor gene p53 causes rhabdomyosarcoma in mice. At the age of 11-21 weeks, all male mice carrying both genetic lesions developed embryonal rhabdomyosarcomas expressing desmin, myosin, and insulin-like growth factor-II, in the genitourinary tract. Our findings led to the hypothesis that the interaction between HER family genes and the p53 pathway might be involved in the origin of human rhabdomyosarcoma.
引用
收藏
页码:2728 / 2732
页数:5
相关论文
共 50 条
  • [1] Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
    Ianzano, Marianna L.
    Croci, Stefania
    Nicoletti, Giordano
    Palladini, Arianna
    Landuzzi, Lorena
    Grosso, Valentina
    Ranieri, Dario
    Dall'Ora, Massimiliano
    Santeramo, Ilaria
    Urbini, Milena
    De Giovanni, Carla
    Lollini, Pier-Luigi
    Nanni, Patrizia
    ONCOTARGET, 2014, 5 (01) : 108 - 119
  • [2] p53 and Her-2/neu in juvenile angiofibromas
    Schick, B
    Veldung, B
    Wemmert, S
    Jung, V
    Montenarh, M
    Meese, E
    Urbschat, S
    ONCOLOGY REPORTS, 2005, 13 (03) : 453 - 457
  • [3] The epidemiology of Her-2/neu and P53 in breast cancer
    Bernstein, JL
    López-Carrillo, L
    Wang, L
    SALUD PUBLICA DE MEXICO, 1999, 41 : S114 - S123
  • [4] P-GLYCOPROTEIN, HER-2/NEU, AND MUTANT P53 EXPRESSION IN HUMAN GYNECOLOGIC TUMORS
    SCHNEIDER, J
    RUBIO, MP
    BARBAZAN, MJ
    RODRIGUEZESCUDERO, FJ
    SEIZINGER, BR
    CASTRESANA, JS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 850 - 855
  • [5] HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
    Reilly, RT
    Gottlieb, MBC
    Ercolini, AM
    Machiels, JPH
    Kane, CE
    Okoye, FI
    Muller, WJ
    Dixon, KH
    Jaffee, EM
    CANCER RESEARCH, 2000, 60 (13) : 3569 - 3576
  • [6] p53 and HER-2/neu overexpression in ovarian borderline tumors
    Eltabbakh, GH
    Belinson, JL
    Kennedy, AW
    Biscotti, CV
    Casey, G
    Tubbs, RR
    GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 218 - 224
  • [7] P53, Her-2/neu and VEGF determined immunohisochemically in chondrosarcoma
    Kharatishvily, TK
    Stepanova, E
    Mousaev, ER
    Aliev, MD
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 274 - 274
  • [8] IMMUNOHISTOCHEMICAL ANALYSIS OF P53 AND HER-2/NEU PROTEINS IN HUMAN TUMORS
    CHANG, K
    DING, I
    KERN, FG
    WILLINGHAM, MC
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1991, 39 (09) : 1281 - 1287
  • [9] Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice
    Jacob, Jennifer
    Radkevich, Olga
    Forni, Guido
    Zielinski, John
    Shim, David
    Jones, Richard F.
    Wei, Wei-Zen
    CELLULAR IMMUNOLOGY, 2006, 240 (02) : 96 - 106
  • [10] Predictive value of p53 and Her-2/neu proteins in patients with breast cancer
    不详
    BREAST, 2005, 14 : S21 - S21